The Microcap Kitchen: Stocks 5¢ to $5 | Stock Discussion Forums

SiliconInvestor

sponsor

Sponsor

Microcap & Penny Stocks | The Microcap Kitchen: Stocks 5¢ to $5

Previous 10 | Next 10

From: Catfish	10/12/2011 2:32:50 PM
	of 111090

CXM - Another very good article on the promise of CXM. http://www.otcequity.com/?p=1352 Cardium Therapeutics (AMEX: CXM) Receives FDA Clearance to Market and Sell Excellagen, Technology Platform Could Birth New Product Lines Posted on October 12, 2011 by Editor Cardium Therapeutics (AMEX: CXM) has been battling for nearly two years to receive 510(k) clearance from the FDA to market and sell their Excellagen professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds and that positive news was finally announced on Monday, sending shares up more than 223% to a high of 0.42 on trading volume that topped 9 million. The good times spilled over into Tuesday for the small biomedical company as shares climbed to a high of 0.52 before closing the day at 0.40 as many shareholders who had grown accustomed to shares in the mid-0.20 range opted to take their profits. Shares continued to drop on Wednesday, moving around the 0.36 – 0.39 level, and while the fall may be a bit disconcerting for longtime shareholders it could represent a perfect opportunity for those investors looking to find a favorable entry mark. What makes CXM so attractive isn’t just the fact that they will now be able to market and sell Excellagen; it’s also the fact that the small bio-tech has managed to travel the long road without accumulating massive debt. CXM is currently carrying minimal debt while holding about $4.4 million in cash, an enviable position for a company that now has a real opportunity to generate revenues. In all likelihood those revenues will initially come from the treatment of diabetic foot ulcers (DFUs) which represent an $800 million market opportunity in the United States alone. Given the fact that the incidence of diabetes continues to climb on a global scale, with an estimated 300 million expected to have the disease by 2025, the unique ability of Excellagen to significantly accelerate wound healing among those who develop DFUs compared to patients receiving standard of care therapy could truly establish it as a preferred method of treatment in the medical field. Just as exciting as the opportunities in the DFU market, CXM has already begun to look for ways to establish the Excellagen technology platform to additional wound care and product opportunities. In their press release announcing the 510(k) clearance CXM also noted that Excellagen had been “cleared for use in the management of other dermal wounds including partial and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh’s surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds.” By gaining this additional clearance Excellagen isn’t limited to the 1.3 million Americans who are expected to develop DFUs; these other dermal wounds open the door to an additional 92 million patients that could be treated with the Excellagen technology platform. This technology platform has a distinct advantage over other collagen-based wound management products available for professional use in the United States in that the manufacturing process of the Excellagen product allows for sterile fill of ready-to-use, single-use syringes for topical application rather than the more common collagen-based products that include granulated collagens that require mixing prior to use. What CXM was able to show in their Matrix clinical study was that “formulated collagen can significantly accelerate reductions in wound radius immediately following application compared to standard of care therapy in diabetic foot ulcers, and can support platelet activation and release of the wound healing protein, Platelet-Derived Growth Factor (PDGF).” By opting for this form of treatment the 1 in 5 patients who currently require amputation due to DFUs becoming infected could be dramatically reduced. In addition to Excellagen CXM is also advancing their late-stage/registration Aspire clinical study for their Generx angiogenic therapy as a potential new treatment option for patients with myocardial ischemia due to advanced coronary disease. This DNA-based angiogenic therapy is designed to stimulate and promote the growth of supplemental collateral vessels to enhance myocardial blood flow (perfusion) following a one-time intracoronary administration from a standard cardiac infusion catheter in patients who have insufficient blood flow due to atherosclerotic plaque build-up in the coronary arteries. CXM has already received clearance from the Russian Ministry of Health and Social Development to commence a Phase 3 registration study for Generx and favorable findings related to the Aspire study could be useful for optimizing and broadening commercial development pathways in other industrialized countries. CXM is also working to expand their MedPodium product line of premium science-based, easy to use medicinals, neurologics, metabolics, nutraceuticals and aesthetics designed to promote and manage personal health. CXM has created MedPodium Health Sciences, Inc. as a wholly-owned subsidiary designed to develop their nutraceutical and healthy lifestyle products as well as acquire complementary business assets having existing revenues and channels of distribution. MedPodium Health Sciences will also handle the sales and distribution of Excellagen, an obvious benefit to shareholders. It has been a long road for CXM and their shareholders and with a number of obstacles placed before them during this journey share price has been hammered yet it appears as if they are beginning to see the light at the end of the tunnel. FDA clearance alone should trigger favorable investor interest and as the company advances their efforts to market and sell Excellagen and in turn move forward with their other endeavors shares should climb nicely. By all indications shares are a bargain right now and there’s no reason to believe that CXM won’t aggressively pursue the revenue opportunities that are now before them.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: GARY P GROBBEL	10/13/2011 6:26:19 AM
	of 111090

SVA.V, , SEOVF.pk $.11 per sh-I have briefly mentioned their 'cell-pouch' system which addresses the projected $8 BILLION market for regenerative medicine/cell therapies. This medical device is unique and that is something I always look for and the company's Sertolin platform could eliminate the need for anti-rejection drugs. That is one helluva combination. Human trials coming very soon-below is presentation at European conf few days ago- CELL POUCH SYSTEM The Cell Pouch System(TM) is a proprietary medical device which may offer a significant improvement over the current practice of injecting therapeutic cells into blood vessels. Based on pre-clinical studies in four models, the Cell Pouch System(TM) becomes a vascularised organ-like endocrine structure when placed in the body under the skin, providing the microcirculation thought to be essential to early function and long-term survival of therapeutic cells. Sernova has conducted efficacy studies in stringent small and large animal models of diabetes and has shown the device with insulin-producing islets controls blood glucose levels long-term, eliminating the need for daily insulin injections. This has now been demonstrated in isograft, autograft (self-tissue) and allograft (donor tissue) studies using substantially lower doses of islets than typically used for portal vein delivery, the current standard of care. Furthermore, Sernova believes the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases and is currently seeking corporate partnerships as part of a strategy to demonstrate the broad utility of the Cell Pouch System(TM). sernova.com

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Catfish	10/13/2011 8:41:14 AM
	of 111090

WGBS - .28 This may get some interest today....and the stock is cheap. WaferGen SmartChip System Chosen to Confirm Accuracy of New Blood Test Under Development for Detection of Cancer and Other Diseases Results published by German scientists in Nature Methods By: PR Newswire Oct. 13, 2011 08:30 AM FREMONT, Calif., Oct. 13, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTCBB:WGBS), the provider of next-generation genomic analysis systems, announced that its SmartChip Real-Time PCR System was chosen by a German consortium to advance their research toward developing a reliable blood test for detection of cancer, cardiovascular and other diseases. The results of the multicenter study were published in Nature Methods by a broad group of scientists headed by Andreas Keller at Febit Biomed GMBH and the Comprehensive Biomarker Center (CBC, Heidelberg). The researchers turned to WaferGen's SmartChip System to validate their findings of significantly different microRNA levels in blood of tumors compared to those found in healthy subjects. Most microRNA expression profiles come from solid tissue samples. The purpose of this study was to assess if different microRNA expression levels could be determined in blood samples. Using the SmartChip System, they were able to confirm variations in microRNA levels from 44 individuals with lung cancer and 41 with COPD (chronic obstructive pulmonary disease). These research results and verification by the SmartChip System support the potential of using microRNA expression patterns in blood to detect disease. "We have been astonished by the high degree of reproducibility of the SmartChip System and the concordance with the microarray data," said Keller. "We applaud the CBC, Heidelberg and the German team who have made this outstanding progress toward developing a blood test for what could be early detection - and thereby more successful treatment - of cancer and other diseases," said David Gelfand, Ph.D., Chief Scientific Officer, WaferGen. "Although there is still additional development work that needs to be conducted, we are pleased to have helped to move closer to making this important test a reality. It is indicative of the role of our SmartChip System as a transformative genomic analysis product." MicroRNAs are small non-protein-coding single-stranded RNA molecules of 20-24 nucleotides in length that function as negative regulators of gene expression by targeting specific messenger RNAs. This either inhibits translation or promotes messenger RNA degradation. By understanding the relationship between disease processes and microRNA patterns in blood cells, scientists believe they can better comprehend diseases. To read the complete article, see: Andreas Keller et al: "Towards discovering the blood-borne miRNome of human diseases." Nature Methods 2011, DOI:10.1038/nmeth.1682. About WaferGen and the SmartChip Real-Time PCR System WaferGen Biosystems, Inc., an emerging genomic analysis company in the early stage of commercialization, offers the transformative SmartChip Real-Time PCR System--a next-generation Real-Time PCR system for profiling and validation of gene expression patterns (biomarkers) on a single platform. The SmartChip System provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling and Single Nucleotide Polymorphism (SNP) genotyping. WaferGen also offers Quick-Turnaround SmartChip Custom (User-Defined) Panels to enable validation studies of specific genes of interest through customization of high-throughput, real-time PCR SmartChip assay panels--all on a quick-turnaround basis. In addition, the company offers an innovative fee-based service for gene-expression profiling using the SmartChip System. For additional information, please see http://www.wafergen.com . Forward Looking Statements This press release contains certain "forward-looking statements". Such statements relating to the use of the SmartChip System, and other statements relating to future events are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company may need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2010 and the company's most recent Quarterly Report on Form 10-Q for the period ended June 30, 2011. Security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. WaferGen Contacts 510-651-4450 Don Huffman, CFO don.huffman@wafergen.com Media: Joyce Strand joyce.strand@wafergen.com Investors: Tim Ryan tryan@shorehamgroupllc.com 212-242-7777 SOURCE WaferGen Biosystems, Inc.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: MikeS97707	10/13/2011 10:42:30 AM
	of 111090

TechPrecision Corporation to Present at Sixth Annual Singular Research "Best of the Uncovereds" Conference October 26, 2011 On Thursday October 13, 2011, 10:36 am CENTER VALLEY, Pa., Oct. 13, 2011 /PRNewswire/ -- TechPrecision Corporation (OTC Bulletin Board:TPCS.ob - News) ("TechPrecision", or "the Company"), an industry leading manufacturer of precision, large-scale fabricated and machined metal components and systems with customers in the alternative energy, cleantech, medical, nuclear, defense, aerospace and other commercial industries, today announced that it will be presenting at the Singular Research sixth annual "Best of the Uncovereds" Conference on Wednesday, October 26th in Los Angeles. Richard Fitzgerald, the Company's chief financial officer, is scheduled to present at 3 p.m. ET (12 p.m. PDT). The Company will also provide a live webcast of this presentation at singularresearch.com. During the remainder of the day, TechPrecision management will meet with investors during a series of one-on-one breakout meetings at the conference. Interested parties should contact Singular to schedule a meeting. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles. About Singular Research Singular Research aims to be the most trusted supplier of independent, trusted, single-source research on small-to-micro cap companies to the small-to-medium sized Hedge Fund manager. Singular will provide quarterly updates for 20 to 50 companies and make recommendations. Singular's goal is to provide initiation reports and quarterly updates for approximately 40 micro to small cap companies. Singular's Independent analysts have no financial interest in the stocks it covers. Analysts are compensated based on the accuracy of their research calls not through trading commissions or potential deal flow. Since inception in August 2004 Singular Research is up 151.53% through December 2010, compared to the S&P 500 at 13.90%. For more information, visit singular-research.com For more information about the conference, please contact: Robert Maltbie, CFA Singular Research 818-222-6915 robert@singularresearch.com About TechPrecision Corporation TechPrecision Corporation, through its wholly owned subsidiaries, Ranor, Inc., and Wuxi Critical Mechanical Components Co., Ltd., is an industry leading, global manufacturer of precision, large-scale fabricated and machined metal components and systems. These products are used in a variety of markets including: renewable energy (solar and wind), medical, nuclear, defense, industrial, and aerospace. TechPrecision's mission is to be the leading end-to-end global service provider to its markets by furnishing custom, fully integrated "turn-key" solutions for complete products that require custom fabrication, precision machining, assembly, integration, inspection, non-destructive evaluation and testing. To learn more about the Company, please visit the corporate website at techprecision.com. Information on the Company's website or any other website does not constitute a part of this press release. Company Contact: Investor Relations Contact: Mr. Richard F. Fitzgerald Hayden IR Chief Financial Officer Brett Maas TechPrecision Corporation Phone: 646-536-7331 Tel: 1- (484) 693-1702 Email: brett@haydenir.com Email: Fitzgeraldr@techprecision.com www.techprecision.com

Share	Recommend \| Keep \| Reply \| Mark as Last Read

Previous 10 | Next 10

Copyright/IP Policy

Copyright © 1995-2013 Knight Sac Media. All rights reserved.